Spatially explicit prioritization of human antibiotics and antineoplastics in Europe

Environment International

Volumn 51, Issue , 2013, Pages 13-26

  Oldenkamp, Rik ^a   Huijbregts, Mark A J ^a   Hollander, Anne ^a,b   Versporten, Ann ^c   Goossens, Herman ^c   Ragas, Ad M J ^a,d  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d OPEN UNIVERSITY OF THE NETHERLANDS   (Netherlands)

Author keywords

Environment; Human health; Pharmaceuticals; Prioritization; Risk assessment; Spatial variation

Indexed keywords

DRUG PRODUCTS; HEALTH; HEALTH RISKS; RISK ASSESSMENT; SURFACE WATERS;

ANTINEOPLASTICS; AQUATIC ENVIRONMENTS; BEHAVIORAL CHARACTERISTICS; CIPROFLOXACIN; CONSUMPTION PATTERNS; DOXYCYCLINE; ENVIRONMENT; HUMAN HEALTH; LEVOFLOXACIN; MONITORING ACTIVITIES; NORTHERN ITALY; PRIORITIZATION; SCREENING TOOL; SPATIAL VARIATIONS; SPATIALLY EXPLICIT;

ANTIBIOTICS;

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CIPROFLOXACIN; DOXYCYCLINE; DRINKING WATER; LEVOFLOXACIN; SURFACE WATER;

ANTIBIOTICS; DRINKING WATER; DRUG; PRIORITIZATION; RISK ASSESSMENT; SPATIAL VARIATION;

AQUATIC ENVIRONMENT; ARTICLE; BEHAVIOR; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG USE; ENVIRONMENTAL MONITORING; EUROPE; FOOD INTAKE; FRANCE; GERMANY; HEALTH; HEALTH HAZARD; HEALTH RISK QUOTIENT; HUMAN; NONHUMAN; POLAND; POLLUTION; PREDICTION; PRIORITY JOURNAL; RESEARCH; RISK ASSESSMENT; SCREENING TEST; SEWAGE TREATMENT; SPAIN; SWEDEN; UNITED KINGDOM; WATER CONTAMINATION; WATER TREATMENT;

EUROPE;

EID: 84868323064     PISSN: 01604120     EISSN: 18736750     Source Type: Journal    
DOI: 10.1016/j.envint.2012.09.010     Document Type: Article

References (125)

1. Accelrys Inc Registry of Toxic Effects of Chemical Substances (RTECS) 2011, Available from: http://ccinfoweb.ccohs.ca/rtecs/search.html. Accessed at 19 Aug 2011, Canadian Centre for Occupational Health and Safety CCOHS.
2. Adriaenssens N., Coenen S., Muller A., Vankerckhoven V., Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): outpatient systemic antimycotic and antifungal use in Europe. J Antimicrob Chemother 2010, 65:769-774.
3. Adriaenssens N., Coenen S., Versporten A., Muller A., Minalu G., Faes C., et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997-2009). J Antimicrob Chemother 2011, 66(Suppl. 6):vi3-vi12.
4. Adriaenssens N., Coenen S., Versporten A., Muller A., Minalu G., Faes C., et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe (1997-2009). J Antimicrob Chemother 2011, 66(Suppl. 6):vi37-vi45.
5. Adriaenssens N., Coenen S., Versporten A., Muller A., Minalu G., Faes C., et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe (1997-2009). J Antimicrob Chemother 2011, 66(Suppl. 6):vi47-vi56.
6. Al-Ahmad A., Daschner F.D., Kümmerer K. Biodegradability of cefotiam, ciprofloxacin, meropenem, penicillin G, and sulfamethoxazole and inhibition of waste water bacteria. Arch Environ Contam Toxicol 1999, 37:158-163.
7. Backhaus T., Scholze M., Grimme L.H. The single substance and mixture toxicity of quinolones to the bioluminescent bacterium Vibrio fischeri. Aquat Toxicol 2000, 49:49-61.
8. 2 processes. Chemosphere 2003, 50:85-95.
9. Batt A.L., Kim S., Aga D.S. Comparison of the occurrence of antibiotics in four full-scale wastewater treatment plants with varying designs and operations. Chemosphere 2007, 68:428-435.
10. Bercu J.P., Parke N.J., Fiori J.M., Meyerhoff R.D. Human health risk assessments for three neuropharmaceutical compounds in surface waters. Regul Toxicol Pharmacol 2008, 50:420-427.
11. Besse J.-P., Garric J. Human pharmaceuticals in surface waters: implementation of a prioritization methodology and application to the French situation. Toxicol Lett 2008, 176:104-123.
12. Birak P., Yurk J., Adeshina F., Lorber M., Pollard K., Choudhury H., et al. Travis and Arms revisited: a second look at a widely used bioconcentration algorithm. Toxicol Ind Health 2001, 17:163-175.
13. Boxall A.B. Veterinary medicines and the environment. Handb Exp Pharmacol 2010, 291-314.
14. Boxall A.B.A., Kolpin D.W., Halling-Sørensen B., Tolls J. Peer reviewed: are veterinary medicines causing environmental risks?. Environ Sci Technol 2003, 37:286A-294A.
15. Cabello F.C. Heavy use of prophylactic antibiotics in aquaculture: a growing problem for human and animal health and for the environment. Environ Microbiol 2006, 8:1137-1144.
16. Calamari D., Zuccato E., Castiglioni S., Bagnati R., Fanelli R. Strategic survey of therapeutic drugs in the Rivers Po and Lambro in Northern Italy. Environ Sci Technol 2003, 37:1241-1248.
17. Castiglioni S., Pomati F., Miller K., Burns B.P., Zuccato E., Calamari D., et al. Novel homologs of the multiple resistance regulator marA in antibiotic-contaminated environments. Water Res 2008, 42:4271-4280.
18. Choong A.M., Teo S.L., Leow J.L., Koh H.L., Ho P.C. A preliminary ecotoxicity study of pharmaceuticals in the marine environment. J Toxicol Environ Health A 2006, 69:1959-1970.
19. Christen V., Hickmann S., Rechenberg B., Fent K. Highly active human pharmaceuticals in aquatic systems: a concept for their identification based on their mode of action. Aquat Toxicol 2010, 96:167-181.
20. Christensen F.M. Pharmaceuticals in the environment-a human risk?. Regul Toxicol Pharmacol 1998, 28:212-221.
21. Christensen A.M., Faaborg-Andersen S., Ingerslev F., Baun A. Mixture and single-substance toxicity of selective serotonin reuptake inhibitors toward algae and crustaceans. Environ Toxicol Chem 2007, 26:85-91.
22. Coenen S., Muller A., Adriaenssens N., Vankerckhoven V., Hendrickx E., Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): outpatient parenteral antibiotic treatment in Europe. J Antimicrob Chemother 2009, 64:200-205.
23. Cooper E.R., Siewicki T.C., Phillips K. Preliminary risk assessment database and risk ranking of pharmaceuticals in the environment. Sci Total Environ 2008, 398:26-33.
24. Cunningham V.L., Binks S.P., Olson M.J. Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment. Regul Toxicol Pharmacol 2009, 53:39-45.
25. Daughton C.G., Ternes T.A. Pharmaceuticals and personal care products in the environment: agents of subtle change. Environ Health Perspect 1999, 107(Suppl. 6):907-938.
26. Diamond J.M., Latimer H.A., Munkittrick K.R., Thornton K.W., Bartell S.M., Kidd K.A. Prioritizing contaminants of emerging concern for ecological screening assessments. Environ Toxicol Chem 2011, 30:2385-2394.
27. Doerr-MacEwen N.A., Haight M.E. Expert stakeholders' views on the management of human pharmaceuticals in the environment. Environ Manage 2006, 38:853-866.
28. Dolliver H., Gupta S. Antibiotic losses in leaching and surface runoff from manure-amended agricultural land. J Environ Qual 2008, 37:1227-1237.
29. EC Council Directive 86/278/EEC of 12 June 1986 on the protection of the environment, and in particular of the soil, when sewage sludge is used in agriculture 1986, European Commission.
30. EC Council Directive 98/83/EC on the quality of water intended for human consumption 1998, European Commission.
31. EC Directive 2001/83/EC of the European parliament and of the council on the community code relating to medicinal products for human use 2001, European Commission.
32. ECDC European Surveillance of Antimicrobial Consumption network (ESAC-Net) 2012, Available from: http://www.ecdc.europa.eu/en/activities/surveillance/ESAC-Net/Pages/index.aspx, European Centre for Disease Prevention and Control.
33. EEA Water resources across Europe-confronting water scarcity and drought 2009, European Environment Agency, Copenhagen, Denmark.
34. EEA UWWTD-WaterBase 2011, Available from: http://www.eea.europa.eu/data-and-maps/data/waterbase-uwwtd-urban-waste-water-treatment-directive-1. Accessed at 19 May 2011, European Environmental Agency.
35. EMA Trends in the sales of veterinary antimicrobial agents in nine European countries (2005-2009) 2011, European Medicines Agency, London, United Kingdom.
36. EMEA Antibiotic resistance in the European Union associated with therapeutic use of veterinary medicines. Report and qualitative risk assessment by the Committee for Veterinary Medicinal products 1999, European Agency for the Evaluation of Medicinal Products EMEA, London, UK.
37. EMEA Guideline on the environmental risk assessment of medicinal products for human use 2006, European Medicines Agency, London, United Kingdom.
38. Enick O.V., Moore M.M. Assessing the assessments: pharmaceuticals in the environment. Environ Impact Assess 2007, 27:707-729.
39. EPA US Estimation programs interface suite™ for Microsoft® Windows 2011, United States Environmental Protection Agency, Washington DC, USA.
40. EPA US ECOTOX database 2011, Available from: http://cfpub.epa.gov/ecotox/. Accessed at 18 Aug 2011, United States Environmental Protection Agency.
41. ESS European social survey round 2: European social survey round 2 data. Data file edition 3.2 2004, Available from: http://ess.nsd.uib.no/ess/round2/. Accessed at 29 July 2011, Norwegian Social Science Data Services, Norway, Data Archive and distributor of ESS data.
42. Eurostat Agricultural use of sewage sludge from urban wastewater [ten00031] 2011, Available from: http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&init=1&language=en&pcode=ten00031&plugin=0. Accessed at 13 July 2011, European Union.
43. Eurostat Annual water abstraction by source and by sector [env_watq2] 2011, Available from: http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=env_watq2&lang=en. Accessed at 3 Nov 2011, European Union.
44. Eurostat Population on 1 January by age and sex [demo_pjan] 2011, European Union.
45. Eurostat Total sewage sludge production from urban wastewater [ten00030] 2011, Available from: http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&init=1&language=en&pcode=ten00030&plugin=0. Accessed at 13 July 2011, European Union.
46. FASS Läkemedelsportalen FASS.se (in Swedish) 2012, Available from: http://http://www.fass.se/LIF/home/index.jsp. Accessed at 21 Aug 2012, LIF, Stockholm, Sweden.
47. Fatta-Kassinos D., Meric S., Nikolaou A. Pharmaceutical residues in environmental waters and wastewater: current state of knowledge and future research. Anal Bioanal Chem 2011, 399:251-275.
48. Fent K., Weston A.A., Caminada D. Ecotoxicology of human pharmaceuticals. Aquat Toxicol 2006, 76:122-159.
49. Fick J., Lindberg R.H., Tysklind M., Larsson D.G. Predicted critical environmental concentrations for 500 pharmaceuticals. Regul Toxicol Pharmacol 2010, 58:516-523.
50. Franco A., Trapp S. Estimation of the soil-water partition coefficient normalized to organic carbon for ionizable organic chemicals. Environ Toxicol Chem 2008, 27:1995-2004.
51. Franco A., Trapp S. A multimedia activity model for ionizable compounds: validation study with 2,4-dichlorophenoxyacetic acid, aniline, and trimethoprim. Environ Toxicol Chem 2010, 29:789-799.
52. Fu W., Franco A., Trapp S. Methods for estimating the bioconcentration factor of ionizable organic chemicals. Environ Toxicol Chem 2009, 28:1372-1379.
53. Golet E.M., Xifra I., Siegrist H., Alder A.C., Giger W. Environmental exposure assessment of fluoroquinolone antibacterial agents from sewage to soil. Environ Sci Technol 2003, 37:3243-3249.
54. Golsteijn L., Hendriks H.W.M., van Zelm R., Ragas A.M.J., Huijbregts M.A.J. Do interspecies correlation estimations increase the reliability of toxicity estimates for wildlife?. Ecotoxicol Environ Saf 2012, 80:238-243.
55. Halling-Sørensen B., Nors Nielsen S., Lanzky P.F., Ingerslev F., Holten Lützhøft H.C., Jørgensen S.E. Occurrence, fate and effects of pharmaceutical substances in the environment-a review. Chemosphere 1998, 36:357-393.
56. Hendriks A.J., Smítková H., Huijbregts M.A.J. A new twist on an old regression: transfer of chemicals to beef and milk in human and ecological risk assessment. Chemosphere 2007, 70:46-56.
57. Hollander A., Sauter F., den Hollander H., Huijbregts M., Ragas A., van de Meent D. Spatial variance in multimedia mass balance models: comparison of LOTOS-EUROS and SimpleBox for PCB-153. Chemosphere 2007, 68:1318-1326.
58. Holten Lützhøft H.C., Halling-Sørensen B., Jørgensen S.E. Algal toxicity of antibacterial agents applied in Danish fish farming. Arch Environ Contam Toxicol 1999, 36:1-6.
59. Huggett D.B., Cook J.C., Ericson J.F., Williams R.T. A theoretical model for utilizing mammalian pharmacology and safety data to prioritize potential impacts of human pharmaceuticals to fish. Hum Ecol Risk Assess 2003, 9:1789-1799.
60. Huschek G., Hansen P.D., Maurer H.H., Krengel D., Kayser A. Environmental risk assessment of medicinal products for human use according to European Commission recommendations. Environ Toxicol 2004, 19:226-240.
61. IEEP Report on the Implementation of the Sewage Sludge Directive 86/278/EEC 2009, Institute for European Environmental Policy.
62. Jiang M., Wang L., Ji R. Biotic and abiotic degradation of four cephalosporin antibiotics in a lake surface water and sediment. Chemosphere 2010, 80:1399-1405.
63. Jones O.A., Voulvoulis N., Lester J.N. Human pharmaceuticals in the aquatic environment a review. Environ Technol 2001, 22:1383-1394.
64. Jørgensen S.E., Halling-Sørensen B. Drugs in the environment. Chemosphere 2000, 40:691-699.
65. 14C-labeled antibiotics in a modified laboratory scale sewage treatment plant at environmentally relevant concentrations. Environ Sci Technol 2006, 40:318-324.
66. Kasprzyk-Hordern B., Dinsdale R.M., Guwy A.J. Multi-residue method for the determination of basic/neutral pharmaceuticals and illicit drugs in surface water by solid-phase extraction and ultra performance liquid chromatography-positive electrospray ionisation tandem mass spectrometry. J Chromatogr A 2007, 1161:132-145.
67. Kay P., Blackwell P.A., Boxall A.B. Transport of veterinary antibiotics in overland flow following the application of slurry to arable land. Chemosphere 2005, 59:951-959.
68. Kemper N. Veterinary antibiotics in the aquatic and terrestrial environment. Ecol Indic 2008, 8:1-13.
69. Knapp C.W., Dolfing J., Ehlert P.A.I., Graham D.W. Evidence of increasing antibiotic resistance gene abundances in archived soils since 1940. Environ Sci Technol 2009, 44:580-587.
70. Kools S.A., Boxall A., Moltmann J.F., Bryning G., Koschorreck J., Knacker T. A ranking of European veterinary medicines based on environmental risks. Integr Environ Assess Manag 2008, 4:399-408.
71. Kools S.A.E., Moltmann J.F., Knacker T. Estimating the use of veterinary medicines in the European union. Regul Toxicol Pharmacol 2008, 50:59-65.
72. Kostich M.S., Lazorchak J.M. Risks to aquatic organisms posed by human pharmaceutical use. Sci Total Environ 2008, 389:329-339.
73. Kreuzig R., Höltge S., Brunotte J., Berenzen N., Wogram J., Schulz R. Test-plot studies on runoff of sulfonamides from manured soils after sprinkler irrigation. Environ Toxicol Chem 2005, 24:777-781.
74. Kumar A., Xagoraraki I. Pharmaceuticals, personal care products and endocrine-disrupting chemicals in U.S. surface and finished drinking waters: a proposed ranking system. Sci Total Environ 2010, 408:5972-5989.
75. Kümmerer K. Antibiotics in the aquatic environment-a review-part I. Chemosphere 2009, 75:417-434.
76. Kümmerer K. Antibiotics in the aquatic environment-a review-part II. Chemosphere 2009, 75:435-441.
77. Larsen J., Stovring H., Kragstrup J., Hansen D. Can differences in medical drug compliance between European countries be explained by social factors: analyses based on data from the European Social Survey, round 2. BMC Public Health 2009, 9:145.
78. Larsson D.G., de Pedro C., Paxeus N. Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J Hazard Mater 2007, 148:751-755.
79. Le Bris H., Pouliquen H. Experimental study on the bioaccumulation of oxytetracycline and oxolinic acid by the blue mussel (Mytilus edulis). An evaluation of its ability to bio-monitor antibiotics in the marine environment. Mar Pollut Bull 2004, 48:434-440.
80. Li B., Zhang T. Biodegradation and adsorption of antibiotics in the activated sludge process. Environ Sci Technol 2010, 44:3468-3473.
81. López-Serna R., Pérez S., Ginebreda A., Petrović M., Barceló D. Fully automated determination of 74 pharmaceuticals in environmental and waste waters by online solid phase extraction-liquid chromatography-electrospray-tandem mass spectrometry. Talanta 2010, 83:410-424.
82. Molander L., Ågerstrand M., Rudén C. WikiPharma - a freely available, easily accessible, interactive and comprehensive database for environmental effect data for pharmaceuticals. Regul Toxicol Pharmacol 2009, 55:367-371.
83. Mompelat S., Le Bot B., Thomas O. Occurrence and fate of pharmaceutical products and by-products, from resource to drinking water. Environ Int 2009, 35:803-814.
84. Muñoz I., Martínez Bueno M.J., Agüera A., Fernández-Alba A.R. Environmental and human health risk assessment of organic micro-pollutants occurring in a Spanish marine fish farm. Environ Pollut 2010, 158:1809-1816.
85. Oaks J.L., Gilbert M., Virani M.Z., Watson R.T., Meteyer C.U., Rideout B.A., et al. Diclofenac residues as the cause of vulture population decline in Pakistan. Nature 2004, 427:630-633.
86. Pedersen J.A., Soliman M., Suffet I.H. Human pharmaceuticals, hormones, and personal care product ingredients in runoff from agricultural fields irrigated with treated wastewater. J Agric Food Chem 2005, 53:1625-1632.
87. Perazzolo C., Morasch B., Kohn T., Magnet A., Thonney D., Chèvre N. Occurrence and fate of micropollutants in the Vidy Bay of Lake Geneva, Switzerland. Part I: priority list for environmental risk assessment of pharmaceuticals. Environ Toxicol Chem 2010, 29:1649-1657.
88. Phillips P.J., Smith S.G., Kolpin D.W., Zaugg S.D., Buxton H.T., Furlong E.T., et al. Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents. Environ Sci Technol 2010, 44:4910-4916.
89. Pistocchi A., Pennington D. European hydraulic geometries for continental SCALE environmental modelling. J Hydrol 2006, 329:553-567.
90. Placket R.L., Hewlett P.S. Quantal responses to mixtures of poisons. J Roy Stat Soc B 1952, 141-163.
91. Ragas A.M., Oldenkamp R., Preeker N.L., Wernicke J., Schlink U. Cumulative risk assessment of chemical exposures in urban environments. Environ Int 2011, 37:872-881.
92. Research Triangle Institute Methodology for predicting cattle biotransfer factors 2005, Research Triangle Institute, Research Triangle Park, NC, USA.
93. RIVM e-toxBase 2011, National Institute of Public Health and the Environment RIVM.
94. Roberts P.H., Thomas K.V. The occurrence of selected pharmaceuticals in wastewater effluent and surface waters of the lower Tyne catchment. Sci Total Environ 2006, 356:143-153.
95. Roos V., Gunnarsson L., Fick J., Larsson D.G., Ruden C. Prioritising pharmaceuticals for environmental risk assessment: towards adequate and feasible first-tier selection. Sci Total Environ 2012, 421-422:102-110.
96. Sanchez W., Sremski W., Piccini B., Palluel O., Maillot-Maréchal E., Betoulle S., et al. Adverse effects in wild fish living downstream from pharmaceutical manufacture discharges. Environ Int 2011, 37:1342-1348.
97. Sanderson H., Johnson D.J., Reitsma T., Brain R.A., Wilson C.J., Solomon K.R. Ranking and prioritization of environmental risks of pharmaceuticals in surface waters. Regul Toxicol Pharmacol 2004, 39:158-183.
98. Sarmah A.K., Meyer M.T., Boxall A.B. A global perspective on the use, sales, exposure pathways, occurrence, fate and effects of veterinary antibiotics (VAs) in the environment. Chemosphere 2006, 65:725-759.
99. Schrap S.M., Rijs G.B.J., Beek M.A., Maaskant J.F.N., Staeb J., Stroomberg G., et al. Humane en veterinaire geneesmiddelen in Nederlands oppervlaktewater en afvalwater-een screening in 2002 2003, RIZA, Lelystad.
100. Schulman L.J., Sargent E.V., Naumann B.D., Faria E.C., Dolan D.G., Wargo J.P. A human health risk assessment of pharmaceuticals in the aquatic environment. Hum Ecol Risk Assess 2002, 8:657-680.
101. Sim W.J., Lee J.W., Lee E.S., Shin S.K., Hwang S.R., Oh J.E. Occurrence and distribution of pharmaceuticals in wastewater from households, livestock farms, hospitals and pharmaceutical manufactures. Chemosphere 2011, 82:179-186.
102. Struijs J. SimpleTreat 3.0: a model to predict the distribution and elimination of chemicals by sewage treatment plants 1996, National Institute of Public Health and the Environment, Bilthoven.
103. Sumpter J.P. Environmental effects of human pharmaceuticals. Drug Inf J 2007, 41:143-147.
104. Swaving M., de Vries L. Omgaan met waarden onder de detectiegrens 2000, RIKZ/RIZA, Eindhoven.
105. Tamtam F., Mercier F., Le Bot B., Eurin J., Tuc Dinh Q., Clément M., et al. Occurrence and fate of antibiotics in the Seine River in various hydrological conditions. Sci Total Environ 2008, 393:84-95.
106. Taylor D., Poulmaire M. An initial survey of unused and expired medicine take-back schemes in the European Union. Pharmaceutical products in the environment: trends towards lowering occurrence and impact KNAPPE International Conference Nimes, France 2008.
107. Thomas K.V., Hilton M.J. The occurrence of selected human pharmaceutical compounds in UK estuaries. Mar Pollut Bull 2004, 49:436-444.
108. Toldrá F., Reig M. Methods for rapid detection of chemical and veterinary drug residues in animal foods. Trends Food Sci Technol 2006, 17:482-489.
109. Tolls J. Sorption of veterinary pharmaceuticals in soils: a review. Environ Sci Technol 2001, 35:3397-3406.
110. Tong A.Y., Peake B.M., Braund R. Disposal practices for unused medications around the world. Environ Int 2011, 37:292-298.
111. Torniainen K., Tammilehto S., Ulvi V. The effect of pH, buffer type and drug concentration on the photodegradation of ciprofloxacin. Int J Pharm 1996, 132:53-61.
112. TOXNET ChemIDplus database 2011, Available from: http://chem.sis.nlm.nih.gov/chemidplus/. Accessed at 19 Aug 2011, U.S. National Library of Medicine.
113. TOXNET Hazardous Substances Data Bank (HSDB) 2011, Available from: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB. Accessed at 19 Aug 2011, U.S. National Library of Medicine.
114. Trapp S. Modelling uptake into roots and subsequent translocation of neutral and ionisable organic compounds. Pest Manag Sci 2000, 56:767-778.
115. Trapp S., Kulhanek A. Human exposure assessment for food - one equation for all crops is not enough. Phytoremediation Rhizoremediation 2006, Springer Netherlands. M. Mackova, D. Dowling, T. Macek (Eds.).
116. Travis C.C., Arms A.D. Bioconcentration of organics in beef, milk, and vegetation. Environ Sci Technol 1988, 22:271-274.
117. Van de Sande-Bruinsma N., Grundmann H., Verloo D., Tiemersma E., Monen J., Goossens H., et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008, 14:1722-1730.
118. Vasudevan D., Bruland G.L., Torrance B.S., Upchurch V.G., MacKay A.A. pH-dependent ciprofloxacin sorption to soils: interaction mechanisms and soil factors influencing sorption. Geoderma 2009, 151:68-76.
119. Versporten A., Coenen S., Adriaenssens N., Muller A., Minalu G., Faes C., et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient cephalosporin use in Europe (1997-2009). J Antimicrob Chemother 2011, 66(Suppl. 6):vi25-vi35.
120. Wahlberg C., Björlenius B., Paxéus N. Läkemedelsrester i Stockholms vattenmiljö-Förekomst, förebyggande åtgärder och rening av avloppsvatten 2010, Stockholm Vatten.
121. Webb S., Ternes T., Gibert M., Olejniczak K. Indirect human exposure to pharmaceuticals via drinking water. Toxicol Lett 2003, 142:157-167.
122. WHO Anatomical therapeutic chemical (ATC) classification system: guidelines for ATC classification and DDD assignment 2012, Available from: http://www.whocc.no/, WHO Collaborating Centre for Drug Statistics Methodology, Oslo.
123. Wiegel S., Aulinger A., Brockmeyer R., Harms H., Löffler J., Reincke H., et al. Pharmaceuticals in the river Elbe and its tributaries. Chemosphere 2004, 57:107-126.
124. Zorita S., Martensson L., Mathiasson L. Occurrence and removal of pharmaceuticals in a municipal sewage treatment system in the south of Sweden. Sci Total Environ 2009, 407:2760-2770.
125. Zuccato E., Calamari D., Natangelo M., Fanelli R. Presence of therapeutic drugs in the environment. Lancet 2000, 355:1789-1790.